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Summary: Immunity to respiratory virus infection is governed by com-
plex biological networks that influence disease progression and patho-
genesis. Systems biology provides an opportunity to explore and
understand these multifaceted interactions based on integration and
modeling of multiple biological parameters. In this review, we describe
new and refined systems-based approaches used to model, identify,
and validate novel targets within complex networks following influenza
and coronavirus infection. In addition, we propose avenues for exten-
sion and expansion that can revolutionize our understanding of infec-
tious disease processes. Together, we hope to provide a window into
the unique and expansive opportunity presented by systems biology to
understand complex disease processes within the context of infectious
diseases.
Keywords: systems biology, influenza, coronavirus, SARS-CoV, H5N1, H1N1,
MERS-CoV
Introduction
The systems biology paradigm argues that the study of
complex biological systems requires predictions based on
detailed integration of multiple biological parameters includ-
ing genomic, proteomic, clinical, and pathologic experimen-
tal data (1, 2). It argues that reductionist approaches that
focus on individual components within the system are
inherently limited in both scope and potential (3). In con-
trast, systems-based approaches provide the opportunity to
identify novel insights, define systems wide interactions,
and decipher the organization of higher order interaction
networks that regulate the function of complex biological
systems (4). For areas like infectious disease research and
immunology, this approach holds significant promise in
identifying common and unique features driving pathogenic
outcomes in the host and between disparate pathogens
(5–7).
For virulent respiratory viruses like sever acute respira-
tory syndrome (SARS), coronavirus (CoV), and influenza A
virus (IAV), disease outcomes are governed by intricate
interactions between multiple immune and viral processes.
To understand these complex biological responses requires
integration of multiple biological parameters through com-
mon experimental systems, uniform methodologies, and
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variable pathogenic inputs (8). The resulting datasets and
subsequent modeling analysis predict key regulatory check-
points, define protective/pathogenic outcomes, and require
additional rounds of validation, data analysis, and model
refinement, thus highlighting the iterative cycles intended
by systems biology. In this way, the systems biology para-
digm drives understanding of complex systems through
identification of novel, important components.
The approach is not without criticism. Skeptics of systems
biology criticize its high cost, slow pace, and descriptive
results (2). Although these charges reflect the initial devel-
opment of any new field, the complaints are not at the root
of the disillusionment with systems biology. Rather, sub-
scribers of systems biology also overemphasized the limita-
tions of reductionist science and the corresponding lack of
progress in complex diseases treatments for cancer, human
immunodeficiency virus infection, and diabetes (9). Systems
biology was heralded as the evolution and replacement of
these approaches, providing novel insights through hypothe-
sis-neutral and discovery-based approaches (4). However, it
has also been fraught with setbacks and challenges, leading
to criticisms on its reliance on reductionist-based approaches
for validation, lack of hypothesis-driven direction, and
declaration that the entire endeavor as a fishing expedition
with a limited, non-specific catch (9). This conflict high-
lights the great irony of systems biology; an approach
designed to integrate biological data has successfully divided
the scientific field.
Despite the conflict, systems biology and reductionist-
based approaches are not antithetical (10). While the indi-
vidual merits can be argued, the combination of these
approaches has the potential to revolutionize our under-
standing of biology. Reductionist-based science can benefit
from the expansion of understanding generated by the
systems-based approach to link pathways and targets to dis-
ease outcomes. Similarly, systems biology can utilize mecha-
nistic insights and rigorous validation studies derived from
reductionist approaches to refine and expand their models.
In this way, these competing methods can form a symbiotic
relationship and drive forward our understanding of com-
plex biological systems. In this review, we offer a path to
reconcile the systems biology paradigm with reductionist
science employing global tenets, demonstrating specific
examples, and outlining future directions. Our hope is that
this blueprint can provide a bridge between the two
approaches and result in expanded understanding of immu-
nology and infectious disease going forward.
The foundation of systems virology
Although new technologies, high-throughput datasets, and
substantial resources play important roles, the key factor in
the success of a systems biology group is the ability to com-
municate and interact across disciplines. The systems biology
paradigm requires the integration of numerous components
to successfully interrogate and evaluate the connectivity that
exists between biological and genomic information (Fig. 1).
Merging massive biological and clinical correlates with
mathematical and computational modeling followed by vali-
dation and extension represents one of the most challenging
aspects of the systems biology approach. Building a multi-
disciplinary team of independent researchers provides a
means to rapidly integrate these different disciplines; how-
ever, the process is intrinsically difficult and requires dedi-
cated effort and continuous interaction. For example,
mathematical modeling often can exclude 99% of possible
targets, leaving 1% for examination; yet for transcriptional
datasets, this can result in >1000 possible gene targets
which prove unmanageable for testing and validation. Simi-
larly, the absence of mock treatments or sufficient sample
numbers greatly reduces the power and utility of any
































































































Fig. 1. Systems biology requires integration across numerous
components and disciplines. The experimental, modeling, and
validation components utilized within our systems biology program
divided into six functional categories. Each color within the border of
the component signifies the various laboratory groups contributing to
this component generation or analysis. Green – Baric RS (UNC);
Blue – Heise MT (UNC); Red – Kawaoka Y(Wisconsin); Teal – Messer
W(OHSU); Maroon – De Silva A(UNC); Pink – Gale (Univ.
Washington); Purple – Pardo Manuel de Villena (UNC); Black – UNC
Cystic Fibrosis Center; White – Katze (Univ. Washington); Yellow –
Metz (PNNL); Fuchsia – Waters (PNNL); Orange – McWeeney
(OHSU).
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is required to harmonize key issues in study that maintain
experimental and statistical rigor as well as model
performance. In our experience, constant dialog through
multimedia channels, and more importantly, via face-to-face
meetings provides an essential dynamic for developing coor-
dinated experimental and modeling platforms that maintain
statistical rigor, inform across disciplines, and promote key
relationships for program performance. Without this under-
lying foundation, the systems biology paradigm would
ultimately fail to produce any useful insights into biological
functions.
The tenets of our systems biology approach
The basic model of systems biology builds on an iterative
cycle that includes experimental design, high-throughput
sample acquisition, data analysis and integration, predic-
tive modeling, biological validation, and model refine-
ment. From this approach, systems biology was expected
to provide comprehensive knowledge, testable models,
and new insights on improved, personalized care, diag-
nostics, and therapeutics for the treatment of human dis-
eases. In some respects, this goal has been achieved in a
variety of areas including vaccine efficacy, cancer predic-
tions, viral diagnostics and prognostics, and most recently,
infectious diseases (11–16). However, many critics argue
that most systems-based reports are descriptive in nature,
lack functional consequence, and omit necessary biological
validation (2, 9). With this in mind, we applied the
tenets described below to address these criticisms while
maintaining the basic systems biology model structure
(Fig. 2).
Examination of specific contrast
In its infancy, systems biology reports were primarily driven
by the novelty of the technology and computing rather than
the basic biological findings (2). These descriptive reports
had minimal experimental contrast which limits biological
insight providing silage for the critics of the approach. As
the field developed, biologist added significant variation to
their experimental design to generate contrast, but validated
functional consequences remained the exception, rather than
the rule. The main reason for this was the scope of the
contrast. Studies modeling variation between mutant and
wildtype (WT) virus infections could generate hundreds of
differential targets for a specific time point; multiplied over
the time course and infection conditions resulted in too
many targets and not enough validation options.
To address this problem, our group applied specific con-
trast as a means to refine our target list and generate possi-
ble avenues of validation. The first step was to identify
conditions in which specific differences are found in one or
more biological output, but remain similar in other areas.
Examples include difference in global transcription at early/
intermediate/late time points (17), changes to overall lethal-
ity (18), and variation in functional gene subsets across dif-
ferent viral pathogens (19, Menachery VD, Eisfeld AJ, Josset
L, Sims AC, Schaefer A, Proll S, Fan S, Li C, Neumann G,






















Fig. 2. A refined systems biology paradigm layers in targeting and expansion. The standard systems biology paradigm includes an iterative
cycle consisting of experimental design, data integration, predictive modeling, confirmation/validation, and model refinement (Blue circle). The
new approach adds a targeting module that incorporates specific contrasts and biological knowledge to refine and improve the modeling outputs
(Orange circle). Similarly, an expansion module adds the opportunity to explore the insights with further analysis using both systems- and
reductionist-based approaches to derive mechanistic insights (Green circle).
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MM, Webb-Robertson BJ, Shukula AK, Burkett S, Metz TO,
Pickles R, Smith RD, Waters KM, Katze MG, Kawaoka Y, Baric
RS, in review). Using contrast as an initial parameter, model-
ing approaches can then focus on these specific conditions
and time points, removing the majority superfluous data and
extinguishing much of the noise within the system. The
results are refined targets that relate to the specific contrasts
within the systems that we seek to explore.
Incorporation of known modeling and biological data
In the effort to generate novel targets, systems biology
approaches have often ignored known aspects of the experi-
mental systems that they employ. The purpose of this is to
generate data and targets that are not biased by the previous
knowledge base. Although this premise is critically important
for experimental design and data acquisition, target genera-
tion is inherently a biased approach. In the systems biology
landscape, the bias is typically toward mathematical models
built upon expansive biological databases; this methodology
allows generation of novel targets independent of the previ-
ous knowledge bases. However, this approach discounts the
prior experimental understanding and fails to utilize it in
refining targets. Therefore, after the generation of unbiased
gene sets that discriminate between different biological stim-
uli (e.g. different viruses, mutants, age, dose), we sought to
incorporate known correlates into our modeling to refine and
produce better targets for confirmation and validation studies.
An example of this approach is integration of a known viral
protein function or analysis of a process shown to be impor-
tant to the infection. In addition, observation from broad sys-
tems-based studies can also be utilized to refine the predictive
model. In this way, we are able to improve the quality of tar-
get selection for downstream validation studies.
Confirmation and validation of functional consequences
In addition to their descriptive nature, systems biology–based
reports have also been criticized for the lack of experimental
verification. Often, the numerous targets make it nearly
impossible to adequately demonstrate validation of the broad
pathways identified. However, the first two tenets of our sys-
tems biology approach begin to address this scope issue. To
fully address this criticism, our group began by making a dis-
tinction between confirmation and validation. Confirmation,
for our purposes, is verification of the same biological output
by a different method or in a different experimental
condition. For example, array data generated from a cell line
can be confirmed by either real-time reverse transcriptase
polymerase chain reaction of targeted genes or by repeating
the experiment in an independent culture system. In contrast,
validation occurs when initial findings are verified with a dif-
ferent biological output. For example, RNA expression data
can be validated by proteomics and/or immunohistochemical
staining. Together, confirmation and validation are paramount
in our systems biology approach and are necessary to provide
robust verification of systems-based targets. Therefore, we
have added increased emphasis to this area to allow pursuit of
further studies through both iterative studies and the approach
outlined in our final tenet.
Extension by reductionist-based approaches
The iterative model of system biology builds upon validated
targets to refine its approach and to design perturbations to
generate new datasets for analysis. In this way, systems biol-
ogy can produce novel insights, identify complex interactions,
validate targets, and continuously add to our biological under-
standing of infectious disease. However, this process requires
significant capital in terms of both time and resources. Impor-
tantly, continuation of the iterative cycle may not extend the
observed finding, but rather identify new areas to explore.
Therefore, our group examined ways to extend system biol-
ogy findings beyond the iterative cycle by using standard
reductionist techniques. Typically, these experiments query
mechanistic aspects, seeking to identify required viral compo-
nents or molecular processes involved in protective or patho-
genic response and disease outcomes. Examples include
studies of functional assays, identification of structural motifs,
and/or utilization of knockout animals. Together, this
approach effectively provides a second level of validation and
provides similar outputs as reductionist-based studies. In addi-
tion, these types of analysis can be programmed into the itera-
tive cycle of systems biology and provide the perturbation
necessary for the next round of data generation.
When considered collectively, the tenets outlined here do
not represent a monumental shift in the systems biology
model. In fact, many of the elements discussed above have
been employed and advocated for by other systems biology
groups (20). Instead, these tenets provide a means to meld sys-
tems biology and reductionist approaches to move away from
broad, discovery-based, and descriptive analysis and toward
novel insights with validated functional consequence. Using
this modified approach also provides an opportunity for
extended understanding with either systems- or reductionist-
based approaches. The examples highlighted below demon-
strate the efficacy of this methodology and provide a window
into a possible future direction for systems-based analysis.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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Expanding understanding of viral proteins and host
interaction
For decades, virology research has focused on understanding
the function of viral proteins during infection. Utilizing
overexpression systems, functional assays, and a variety of
viral mutants, numerous RNA and DNA virus proteins have
been characterized by reductionist approaches, leading to
important biological findings and translational products like
vaccines and therapeutics. These proteins have primarily
been associated with either the viral life cycle (viral polyme-
rases, structural proteins, etc.) or viral–host interaction like
immune antagonism. However, due to their limited genetic
capacity, RNA viruses typically encode multifunctional pro-
teins that perform numerous processes beyond the scope of
viral replication or immune evasion. Often, identifying these
additional processes may be very difficult to reveal using tra-
ditional reductionist approaches. In these situations, systems
biology provides an opportunity to utilize detailed experi-
mental data to predict and identify novel roles for viral
proteins. This fact is illustrated by our examination of SARS-
CoV open reading frame 6 (ORF6) protein (21).
Previous work from our laboratory and others (22–24)
had established and initially characterized a unique group of
specific ORF proteins at the 3′ end of the SARS-CoV genome
including ORF6. Although non-essential for in vitro replica-
tion, initial screens quickly identified ORF6 as an interferon
antagonist (23). Subsequent experiments established that
ORF6 interfered with signal transducer and activator of tran-
scription 1 (STAT1) signaling via binding karyopherin a2,
trapping both the import factor and its partner in complex
karyopherin b1(25, 26). The resulting block prevented
STAT1 nuclear localization and interfered with induction of
the antiviral state within the host. However, despite its role
in antagonizing the type I interferon (IFN) response, mutant
SARS-CoV lacking ORF6 (DORF6) grows to titers equivalent
to WT in both IFN competent (CALU3) and incompetent
cells (Vero) (21). Similarly, type I IFN pretreatment has only
a modest impact on viral replication of DORF6, resulting in
reduced titers similar to WT SARS-CoV (data not shown).
These results argued that the absence of ORF6 is comple-
mented by the myriad of other SARS-CoV IFN antagonist
(27). However, in vivo infection revealed significant attenua-
tion of DORF6 pathogenesis; notably, this attenuation did
not extend to viral titers within the lung. Together, the data
argued that ORF6 plays a role beyond just IFN antagonism.
To fully investigate the impact of ORF6 on viral infection,
we employed a systems biology–based approach that blended
host RNA expression data with the previously known aspects
of ORF6 function (21). The resulting analysis revealed
enhanced transcription of host genes following DORF6 infec-
tion and identified >6000 differentially regulated gene as
compared with WT. Modeling the data with a focus on gene
ontology confirmed augmented expression of antiviral genes.
However, the results also revealed stark differences in terms
of nuclear signaling, cell proliferation, cell cycle, as well as
metabolic processes, and demonstrated a role for ORF6
beyond just IFN antagonism. Additional analysis filtered the
dataset by the known ability of ORF6 to inhibit karyopherin-
based transport; the resulting modeling revealed important
transcriptional hubs that play a critical role in differential
regulation of cellular processes. These hubs, which include
CREB1, VDR, and p53, were then confirmed in primary human
airway epithelial cultures (HAE) and validated using both
proteomic and chromatin immunoprecipitation approaches.
Together, the results suggested that in addition to IFN antag-
onism, ORF6 regulates several karyopherin-dependent tran-
scriptional hubs and alters host cell processes that impact
SARS-CoV pathogenesis.
The identification of ORF6 activity beyond IFN antago-
nism provided novel targets to analyze during infection. By
exploring and understanding the impact of these host pro-
cesses, we can develop new insights on the viral life cycle
and the subsequent host response. For example, CREB1, VDR,
and p53 have been identified as key regulators mediating
differences between WT and DORF6 virus; knock-out
animals exist for these genes allowing further study and
identification of additional downstream effectors. In addi-
tion, these areas may provide ORF6-based targets for thera-
peutic development of vaccine and drug treatments that may
be effective against SARS and other CoVs. Similarly, Creb1
and p53 have been implicated in impacting influenza patho-
genesis, and therapeutics may also have efficacy against IAV
(28–31). Current efforts in our laboratory seek to confirm
and validate these findings in vivo; modeling mice infected
with DORF6 and WT SARS-CoV provides both confirmation
and prioritization of in vitro generated targets. Combining
these datasets will also provide an avenue for increased
understanding of ORF6 function as well as a means to test
possible therapeutics. These studies are currently ongoing.
The approach taken in these studies has also been used by
other groups to query important aspects of pathogenesis
using mutant viruses; the resulting analysis has provided
novel insights following SARS-CoV (32), HSV-1 (33), and
influenza (34) infection. Together, these studies illustrate a
trend that has implications on future systems-based analysis
of viral proteins. As mentioned previously, one tenet of our
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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approach focuses on contrasts within the system. Using
DORF6 studies as a template (21), mutants with ablated
viral protein activity can be examined and compared with
WT virus to quickly identify differential host gene expres-
sion. These host responses can then be modeled to deter-
mine broad differences based on gene ontology, pathway
disruption, or a variety of other transcription-based categori-
zations. This type of analysis provides a window into the
possible functions of a specific viral protein and an avenue
to begin further studies. Notably, known functions derived
from reductionist approaches can also be integrated into the
modeling which provides both refined targeting as well as
incorporating the second tenet of our systems-based
approach. Next, identified targets can be confirmed and vali-
dated by a variety of approaches including proteomics anal-
ysis, drug treatments, or knock-down studies to demonstrate
functional significance in vitro. Finally, further model refine-
ment and validation can be provided by in vivo systems-based
analysis. Together, these steps outline a blue print for sys-
tems-based characterization of novel viral protein function
and have been initiated for several viral proteins in both
SARS-CoV (ExoN, NSP16, ORF3) and IAV (NS1, PB1, PB2).
Identifying host factors that contribute to pathogenesis
Host responses to virus infection are usually regulated by
oligogenic traits, resulting in disparate disease outcomes fol-
lowing infection. To understand these complex relationships
between viral and host factors, in vivo experimentation repre-
sents an important area of viral pathogenesis research. While
significant insights can be achieved by in vitro analysis, animal
models provide a robust and complex biological system to
evaluate the numerous parameters of pathogenesis including
viral replication, immune cell infiltration, and other systemic
host responses. This fact explains the existence and reliance on
mouse models of infection for numerous viral pathogens
including SARS-CoV and IAV. However, traditional in vivo
studies have focused on either known target genes that regu-
late immunity or have utilized viral mutants for comparative
analysis with WT viruses. The result has been extensive exam-
ination and understanding of innate and adaptive immune
components that regulate viral disease mostly in terms of viral
replication. Meanwhile, elements that regulate other aspects
of viral disease including systemic inflammation, clinical dis-
ease severity, and tissue repair remain undefined and under-
studied. Our systems-based approaches provide an
opportunity and a means to assay these less studied elements.
The systems virology animal model employed by our
group infects 20-week-old C57BL6/J (B6) mice with a dose
range of either SARS-CoV or IAV over a 7-day time course.
Both mouse age and dose range were used to provide a
robust spectrum of disease measurements that included viral
replication kinetics, clinical disease severity, pathology
changes, and variation in host transcript and proteomics.
Using the transcriptomics dataset from both SARS-CoV and
IAV challenge, the modelers analyzed the data with a con-
text likelihood of relatedness method (CLR); this approach
uses correlation of expression profiles to score interactions
between regulator and target genes to generate networks
that encompassed significant elements of in vivo disease (35,
36). For SARS-CoV and IAV, CLR-based methodologies
resulted in identification of differential networks associated
with transcription regulation, chemotaxis, lymphocyte acti-
vation, lipid metabolism, and others (Fig. 3). However, the
results required additional narrowing to identify target path-
ways that could be validated. Therefore, we applied the first
two tenets of our systems biology approach: contrast and
incorporation of biological knowledge.
We focused on the SARS-CoV dataset and used the mea-
sured outputs to identify and explore areas of contrast. In
our examination, we noted similarities between the two
highest SARS-CoV doses in terms of viral replication kinet-
ics, global gene expression changes, and pathology ele-
ments (18). However, these doses sharply diverge in terms
of weight loss at late time points and overall lethality. This
contrast provided an opportunity to explore pathways and
networks that were different between lethal and sublethal
disease. To incorporate these biological data, we utilized a
weighted gene coexpression network analysis (WGCNA);
this approach uses underlying correlation structures to par-
tition gene expression into modules not biased by existing
knowledge bases (37). Connectivity inferred by WGCNA is
a strong predictor of biological function, and the most
highly connected hub genes provide candidate mediators of
disease that have been used in a variety of fields including
cancer, plant, and genetics (37–43). Gene ontology analysis
of this module revealed a strong categorization for extracel-
lular matrix (ECM) remodeling and wound healing path-
ways. While previously shown to be important in lung
diseases (44, 45), these pathways had been largely unstud-
ied within the context of viral respiratory disease. To fur-
ther narrow candidate pathways for confirmation and
validation purposes, we evaluated the connectivity and
module membership within the known biological path-
ways. The resulting analysis found urokinase pathway
enriched by both criteria making it an ideal network for
validation studies.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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Returning to the plethora of systems generated data, we
sought to address our third systems biology tenet: confir-
mation and validation. As a part of the broad ECM remodel-
ing network, the urokinase pathway is primarily associated
with regulation of plasminogen resulting in fibrin degrada-
tion/deposition (46–50). Therefore, we utilized paired in
vivo proteomics data to analyze differences in urokinase
pathway–related components following the lethal and suble-
thal doses. Our results showed a significant increase in sev-
eral urokinase pathway–related proteins during the lethal
dose as compared with the sublethal dose (18). These pro-
teins, which include fibrin chains, fibronectin, and plasmin-
ogen, confirmed enhanced urokinase activity following the
lethal challenge. Similarly, histology staining for fibrin
deposition confirmed augmented staining during lethal
SARS-CoV infection. Finally, we chose to employ a standard
reductionist approach, gene knock-out, to further validate
the role of urokinase pathway in vivo. Mice lacking Serpine1,
an important negative regulator within the urokinase path-
way, were challenged with SARS-CoV and had increased
weight loss, lung hemorrhage, and increased lethality as
compared with control mice. Together, these data confirm
a role for the urokinase pathway in regulating lethal SARS-
CoV disease and validated a target generated by our sys-
tems-based modeling.
The approach taken to characterize the urokinase path-
way’s contribution in protecting from lethal SARS-CoV
disease was built upon the tenets of our systems biology
approach. Collecting unbiased measurements from in vivo
infection, we identified areas of contrast within the SARS-
CoV dataset, modified the models to incorporate this biolog-
ical data, and generated refined targets for confirmation and
validation. This approach clearly demonstrated an important
role for the urokinase pathway in protection against lethal
SARS-CoV infection and may possibly lead to the develop-
ment of therapeutics based on targets within this pathway.
A similar approach has also been used to identify and vali-
date other networks that regulate SARS-CoV and IAV patho-
genesis in vivo; these include complement components (18)
as well as TNFRSF1b (14) and Kepi1 (McDermott JE, Gralinski
LE , Eisfeld AJ, Mitchell HD, Bankhead A, Josset L,
Tchitchek N, Chang J, Neumann G, Tilton SC, Li C, Fan
S, Sch€afer A, McWeeney S, Kawaoka Y, Baric RS, Waters











Fig. 3. Context likelihood of relatedness method reveals functional modules that impact SARS-CoV or influenza infection in vivo. RNA
expression data from in vivo infection of SARS-CoV and H5N1-VN1203 were utilized to infer coexpression networks between genes and help
identify functional modules important during respiratory virus infection. Topological analysis permits identification of bottlenecks of network
communication and provides potential target areas for knockdown studies. Data representative of RNA expression 4-day post-SARS-CoV infection
(100 pfu dose) with red representing upregulation and blue representing downregulation relative to mock.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
262 Immunological Reviews 255/2013
Menachery & Baric  Bugs in the system
the Serpine1/ data provides an avenue for reiterative sys-
tems biology studies and continued model refinement, we
also plan to explore mechanistic and translational aspects of
the urokinase pathway modification using traditional reduc-
tionist-based approaches. Together, the combination of these
two methods provides a means to expand our knowledge
base in two different, but important directions.
The study also illustrates the utility of this systems biol-
ogy–based approach in broadening the scope of viral patho-
genesis research. While the wound healing and ECM
remodeling pathways had been clearly established as impor-
tant to lung disease, traditional viral pathogenesis research
was unlikely to have explored these areas with sufficient
depth to generate strong conclusions. As a result of this
study, the urokinase pathway will likely be the subject of
future experimentation by both systems-based and reduc-
tionist approaches with a variety of pathogen, effectively
expanding the scope of the research. The importance of this
fact should not be diminished as this is a primary goal of
systems biology that is beginning to be achieved.
Revisiting known biological correlates with expanded
depth and breadth
The systems biology paradigm seeks to drive understating of
complex biological systems by incorporating detailed inte-
gration of experimental data to construct models that predict
and identify novel findings (2). However, although identifi-
cation of novel insights is paramount, it would be short
sighted to not apply these vast datasets to other areas of
interest. The effort to collect comparable, unbiased data
across pathogens and platforms provides a unique opportu-
nity to both identify new insights through systems-based
modeling, and reexamine previously charted areas with
increased depth and coverage. Driven by biological intuition
rather than mathematical modeling alone, analysis based on
systems biology data may provide novel insights into well-
studied areas of biology and enhance our understanding of
complex biological systems. The efficacy of this approach is
illustrated in our examination of cytokine responses, most
notably interferon-stimulated gene (ISGs) induction.
Cytokine responses following infection have been exten-
sively studied over the past few decades and have resulted
in well-defined pathways for important processes including
innate and adaptive immunity, inflammation, antiviral
defense, etc. However, insights from these types of studies
are hampered by the lack of uniform platforms, infection
conditions, and data collection methods. Systems virology
datasets alleviated these problems and permit analysis
beyond a single treatment or infection condition. Therefore,
in lieu of the typical unbiased modeling approach, we
incorporated a network with known biological importance
to virus infection: type I IFN and ISGs. Type I IFN induces a
signaling cascade that arms immune defenses and serve to
provide the first line of defense against viral pathogens (51,
52). Upon binding through the type I IFN receptor, IFN
signaling initiates transcription of hundreds of ISGs that
have antiviral, immune modulatory, and cell regulatory
functions. Expression of these genes within host cells
renders an inhospitable antiviral state critical to limiting viral
infection in vitro and in vivo. While several prominent ISGs
such as Mx, PKR, and OAS have been studied in depth, the
vast majority have never been fully evaluated. However,
the ISGs impact on viral infection is clear; in the absence of
the type I IFN cascade, the host fails to mount effective
immune responses and becomes very susceptible to viral
challenge (53). Successful viral pathogens, including SARS-
CoV and IAV, have developed means to overcome specific
IFN and ISG effector functions (27, 54, 55). Globally, ISGs
as a class have broad functions beyond just direct viral
antagonism including increased MHC class I and II expres-
sion, augmented immune infiltration and trafficking, and
host protein shutoff (51). These processes can impede viral
replication and pathogenesis; therefore, viruses likely
attempt to short circuit global ISG induction, potentially
through different means.
With the biological filter set, we next sought to evaluate
the ISG response within the parameters of systems-based
datasets. Because ISGs vary based on cell and tissue type
(56), Calu3 cells were treated with type I IFN to establish a
consensus ISG list specific for respiratory cells. With this list,
we then examined RNA expression of ISGs following SARS-
CoV, IAV H1N1-CA04, and H5N1-VN1203 infection; the
resulting analysis revealed stark differences in terms of ISG
induction between all three respiratory pathogens. Whereas
IAV H1N1-CA04 robustly induced the majority of ISGs
following infection, H5N1-VN1203 actively manipulated
the ISG response with both up- and downregulation of ISG
subsets. Finally, SARS-CoV successfully delayed ISG until
after peak viral titers had been achieved. Together, the data
demonstrated the utility of incorporating known biological
factors as a means to filter and identify novel patterns across
pathogens.
Having established significant differences across IAV and
SARS-CoV strains, we next sought to confirm and validate
these results. Examination of primary HAE demonstrated that
ISG downregulation was maintained for SARS-CoV and that
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robust induction was observed for H1N1-CA04. Proteomics
analysis from Calu3 cells also found robust production of
ISG proteins for both SARS-CoV and H1N1-CA04; however,
ISG protein production was delayed with similar kinetics as
RNA expression following SARS-CoV infection. In contrast,
H5N1-VN1203 infection failed to increase any detectable
ISG production and resulted in reduced protein levels of
ISGs expressed at a basal level. Together, these results vali-
dated the RNA expression analysis with paired protein
measures.
Fulfilling the major tenets of our systems biology
approach, we next sought to expand our studies to explore
the mechanism of action for both SARS-CoV and IAV. To
answer these questions, we utilized reductionist-based
approaches but applied systems generated data where possi-
ble. Using RNA expression data, we asked and confirmed
that ISG delay following SARS-CoV was primarily due to
delayed type I IFN production. Modeling downstream gene
expression patterns, we also determined that H5N1-VN1203
did not target transcriptional factors to mediate ISG antago-
nism. Next, we utilized RNA expression patterns to identify
target genes for differential histone modification. The result-
ing experiment confirmed that H5N1-VN1203 mediated
incorporation of a repressive histone modification in the 5′
untranslated region of downregulated ISGs; this modification
was absent in upregulated ISGs. Having established a role for
epigenetic regulation in the ISG antagonism, we next sought
to identify the involved viral components. Multidimensional
scaling (MDS) analysis, a statistical technique to visualize
similarities and differences between datasets, revealed infor-
mative insights for both SARS-CoV and IAV infection (Fig. 4).
MDS analysis comparing ISG expression following WT and
DORF6 SARS-CoV infection demonstrated little contrast
between the two, suggesting a limited role for ORF6 in glo-
bal ISG antagonism. In contrast, MDS analysis of H5N1
mutants revealed NS1 truncation resulted in closer alignment
with H1N1-CA04 ISG expression than WT; PB1 and PB2
mutants had some change, but aligned closer to the WT.
Subsequent experiments revealed that NS1 truncation ablated
ISG downregulation and no incorporation of the repressive
histone marker. These findings suggest that epigenetic regu-
lation via NS1, in addition to interference with sensing/sig-
naling, contributes to IAV control of the type I IFN response.
Together, these results established novel mechanistic insights
into ISG antagonism by both SARS-CoV and IAV.
The approach outlined in this section marks a significant
departure from the traditional systems biology paradigm
that focuses primarily on novel insights derived from unbi-
ased mathematical modeling. Instead, this methodology
requires well-defined sets of biological phenomena and
effectors (e.g. ISG effector genes, MHC class I/II expression
networks, stress response, apoptotic markers) that are
differentially regulated after virus infection to drive the
analysis forward. In addition, cross-virus comparisons pro-
vide contrast, validation, and variant response networks
which combine to inform hypotheses for future reductionist
A B
Fig. 4. Multidimensional scaling analysis illuminates variation between wildtype and mutant viruses. Multidimensional scaling analysis
provides a statistical method to evaluate ISG expression of a virus relative to the expression from other mutants. Analysis completed on Calu3 cells
following mock (Black), type I interferon treatment (Green), or infection with (A) wildtype (WT) SARS-CoV (Orange), DORF6 (Red) and (B)
WT H5N1-VN1203 (Purple), NS1-trunc124 (Teal), PB1-F2del (Red), PB2-627E (Maroon), and WT H1N1-CA04 (Blue).
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and mechanistic studies. In the case of ISGs, it had been
well established that these genes play an important role dur-
ing viral infection; however, limitations in terms of cell
type, pathogen, and experimental conditions had made anal-
ysis difficult. By applying this question to the systems virol-
ogy dataset, we were able to filter our scope and generate a
robust analysis comparing three highly pathogenic respira-
tory viruses with great depth and coverage. The results
produced novel insights into how these virulent viruses
manipulate an important arm of the immune response and
have major implications for future studies and the develop-
ment of therapeutics.
The study demonstrates the utility of mining the depth
and breadth of systems biology data independent of tradi-
tional systems-based analysis. With this in mind, our group
has initiated similar studies to examine areas known to be
important for viral pathogenesis including inflammation,
cell-cycle regulation, and autophagy. However, the most
important implication may be the ability to duplicate this
approach in examination of other areas of scientific research.
One of the stated goals of systems biology is to provide data-
sets and research tools to the scientific community. However,
although vast datasets are readily available, their utility has
been limited by the complexity and multidisciplinary nature
of traditional systems-based analysis. The approach outlined
here provides a means for traditional scientists to integrate
known biological parameters to filter these massive datasets
into useful, targeted analysis for their specific studies. The
scope of this approach extends beyond just infectious dis-
ease, as other scientific disciplines including lung physiology,
allergy research, and aging might benefit from examining
the systems virology datasets. In this way, the approach
effectively provides accessibility to these datasets and facili-
tates utilization by the scientific community.
Expanding systems-based studies to translational
applications
A major complaint of the systems biology approach is the
glacial pace required to generate novel findings (2).
Working through the systems biology model requires exten-
sive high-throughput data generation, significant modeling
development, and substantial validation experiments to iden-
tify and verify discovery-based hypotheses. Incorporation of
all these components takes significant time and effort
slowing the process for data discovery. However, once
established, the systems-based approach provides an ideal
framework to quickly and accurately examine new experi-
mental conditions utilizing the template from earlier experi-
ments. The result can be rapid evaluation and insights into
novel area of viral infection as illustrated by our examina-
tion of novel Middle East Respiratory Syndrome Coronavirus
(MERS-CoV).
In September 2012, a novel coronavirus, MERS-CoV, was
identified as a causative agent in two cases presenting with
acute respiratory distress and renal failure. Subsequent sur-
veillance revealed 15 additional cases derived from individu-
als either from or having recently traveled to the Middle East
resulting in 11 deaths and a mortality rate or 64.7% (11/
17). The severe respiratory infection coupled with the high
mortality rate quickly drew comparisons with SARS-CoV out-
break in 2002–2003; however, sequence lineage and host
range suggested significant differences between these viruses
(57). In addition, it was quickly established that MERS-CoV
did not use the SARS-CoV entry receptor, human ACE2 (58).
Instead, dipeptidyl-peptidase 4 has been identified as the
functional MERS-CoV entry receptor (59). Other differences
observed between the viruses include cytopathic effect, tissue
tropism, and sensitivity to type I IFN (58, 60). However,
although these initial studies provided a small window into
the pathogenesis of HCoV-EMC, very little data existed
beyond viral characterization. With this in mind, we sought
to examine host responses to MERS-CoV within the context
of our systems virology paradigm (19).
Utilizing the same experimental design that was used for
both SARS-CoV and IAV, human airway cells were infected
with MERS-CoV at a high multiplicity of infection (MOI).
Preliminary screening had confirmed rapid cytopathic effect
in these cells; therefore, samples for viral replication and
RNA analysis were harvested over the first 24 h, mimicking
the time course used for the highly pathogenic H5N1-
VN1203 (61). The results indicated that both SARS-CoV and
MERS-CoV maintain similar levels of viral replication (19).
Although MERS-CoV induced significant cytopathic effects,
both viruses grew to robust, equivalent titers over the time
course. Examination of the host response also revealed broad
similarities between SARS-CoV and MERS-CoV including
biosynthesis/degradation pathways, IL17 activation, and
innate immune recognition.
The host expression profile also indicated major differences
between the viruses in terms of induction kinetics, pathway
activation, and possible viral antagonism. MERS-CoV induced
a much more rapid host response as compared with SARS-
CoV with massive dysregulation by 18- and 24-h postinfec-
tion. Although these gene changes shared some similarities
with SARS-CoV infection at later time point, the data sug-
gested that the global host response is quite distinct between
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the two CoVs, especially in areas that included ubiquitina-
tion, lymphocyte signaling, and antigen presentation. In
addition, we compared MERS-CoV with IAV strains H5N1-
VN1203; the results demonstrated similarities beyond just
high cytopathic effect including similarities in ISG manipula-
tion between the two highly virulent viruses (Menachery VD,
Eisfeld AJ, Josset L, Sims AC, Schaefer A, Proll S, Fan S, Li C,
Neumann G, Tilton SC, Chang J, Gralinski LE, Long C, Green
R, Matzke MM, Webb-Robertson BJ, Shukula AK, Burkett S,
Metz TO, Pickles R, Smith RD, Waters KM, Katze MG,
Kawaoka Y, Baric RS, in review). Together, the rapid assess-
ment of the host response illustrates the utility of systems-
based approaches to newly emergent respiratory virus. By
using specific contrast with systems-based pathogen data and
considering biological correlates like enhanced CPE, the anal-
ysis was able to provide novel insights into the pathogenesis
of this newly emergent MERS-CoV.
With its ability to cause severe respiratory disease and its
high mortality rate, novel drug and vaccines against HCoV-
EMC, as well as future emerging CoVs, are also high priori-
ties. Therefore, we utilized systems-based approaches to
generate and validate therapeutic options for MERS-CoV
infection. Our approach focused on early changes following
infection, identifying upstream regulators and other
compounds that may reverse host expression networks. Dis-
ruption of these networks potentially interferes with impor-
tant aspects of the virus life cycle or replication and could
effectively limit pathogenesis. The analysis resulted in identi-
fication of possible drug targets with significant potential
based on Z-score. We validated the most robust of these tar-
gets, SB203580, demonstrating efficacy against both HCoV-
EMC and SARS-CoV in vitro (19). While in vivo studies in
young and highly vulnerable aged animal models are
needed, the results demonstrated the utility of systems-based
analysis in evaluating novel, emergent viruses and delivered
on some of the promise of this approach in terms of thera-
peutic translation.
Globally, this approach highlights a powerful means to
rapidly evaluate and characterize novel, emergent viruses.
The analysis builds upon the infrastructure of systems biol-
ogy using previously evaluated pathogens to provide a
useful comparison. With these data in hand, MERS-CoV was
rapidly evaluated against the related SARS-CoV in a common
culture system. The result was a plethora of new data that
greatly aided our understanding of the virus/host interac-
tions. In addition, the systems biology data provided the
opportunity to compare the novel CoV with other respira-
tory viruses such as H5N1-VN1203. These comparisons
allow identification of similarities and differences in terms
of host response that might inform treatment and therapeu-
tic options. Similarly, the analysis of multiple pathogens
permits the development of expression signatures associated
with virulence. For example, ISG manipulation by both
H5N1-VN1203 and MERS-CoV could be used as a signature
to rapidly evaluate the pathogenic potential of emergent or
zoonotic viral strains. Similar approaches with other host
expression pathways and the addition of other virulent and
avirulent pathogens across several viral families might pro-
vide a mosaic of signatures to quickly and rapidly assess the
danger posed by a particular emergent pathogen. Together,
the data illustrate that the infrastructure of systems biology
provides a unique and novel platform to evaluate emergent
viruses and demonstrates the rapid analysis not typically
associated with systems-based analysis (62).
Moving systems biology forward
Systems-based approaches have made significant and lasting
contributions to a wide array of scientific fields over the past
decade (11–16). However, with its increased interest,
expanded resources, and refined techniques, systems biology
also has an opportunity to improve its targeting, results, and
global impact. In the past, these advances have relied on
application of new technologies for data generation (2);
however, as systems biology matures, improvement will
require novel approaches in terms of integration, modeling,
and validation in addition to the newest data generation
methods. Below, we highlight elements in each of these
areas and how our group plans to incorporate them to
improve our systems-based approach.
Data expansion
The foundation of systems biology is built upon acquisition of
high-throughput, unbiased datasets from varying experimental
conditions to model and predict important aspects of complex
biological systems. In our initial approach, these studies uti-
lized a blend of uniformity with variability achieved through
common culture and animals systems, uniform experimental
protocols, and variation in viral pathogens. The approach
resulted in diverse, high-throughput datasets that served as the
basis for the development and application of our mathematical
models. Our targets were further refined by other measure-
ments including weight loss, lethality, and cell infiltration via
lung histology. Together, this approach yielded novel insights
that were subsequently confirmed, validated, and expanded.
However, these conditions and readouts represent only a
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fraction of the systems-based datasets that can be generated
and analyzed by this platform.
As we move forward, our group seeks to use expanded
experimental conditions to increase our input database. As
demonstrated by our previous works, comparison across
pathogen has yielded significant insight into respiratory
infection. Whereas our current program has studied a vari-
ety of CoV and IAV precursors as well as mutants, future
work endeavors to explore and compare these families to
other respiratory pathogens including respiratory syncytial
virus (RSV), pathogenic hantaviruses, and other microbial
pathogens. Similarly, we plan to expand our experiments
beyond the Calu3 cell line and HAE cultures used in our
initial studies; primary type II pneumocytes, alveolar macro-
phage cultures, endothelial cells, and infiltrating immune
cell populations are important targets for viral infection, and
their response to infection is likely governed by cell-type
and tissue-specific factors. Exploring this tissue specificity of
respiratory pathogens provides insights into disease progres-
sion, keys to severity, and possible cell-specific targets for
therapeutic development. With regards to in vivo experi-
ments, we plan to use mouse resources like the collaborative
cross (discussed below) and age-dependent models to pro-
vide additional scope and contrast for systems-based analy-
sis. In addition to altered and expanded experimental
conditions, we also plan to increase the measured outputs
available for analysis. In the past, high-throughput data had
been limited to RNA expression and proteomics data;
moving forward, the newest technologies provide the
opportunity to assess complex readouts like host genetic var-
iation or phenotypic readouts like respiratory function, cell
infiltration, phosphoproteomics, and metabolism. Together,
these expanded experimental conditions and readouts repre-
sent just a few areas that systems biology can use moving
forward to reveal complex insights into disease pathogenesis
and severity. Below, we briefly describe the application of
the data expansion tools to our systems-based approaches.
The collaborative cross
Genetic variation plays a critical role in human disease as
demonstrated by numerous genome-wide association stud-
ies (GWAS) for a variety of ailments. However, exploring
genetic diversity had been limited by the lack of experi-
mental systems that model human outbred populations.
The collaborative cross (CC), a novel panel of approxi-
mately 300 genetically related recombinant inbred lines,
solves these problems as it was designed to model genetic
diversity in outbred populations like humans (63–68).
Derived from eight founder lines, the CC provides exten-
sive variation [47 million single nucleotide polymorphisms
(SNP) and 4 million insertions/deletions, on the same
order as those observed in the human genome], high
reproducibility of genetically identical mouse lines, and
customization via inbred intercrosses. Screening infectious
disease outcomes in this resource provides the opportunity
to understand how genetic variation within a population
affects the host response to viral infection. Importantly,
the CC is powerful enough to untangle the role of mono-
genic and oligogenetic traits in complex disease pheno-
types by providing a diverse range of independent
readouts ideal for modeling areas like inflammation,
innate immunity, and lymphocyte responses (67). For
example, SARS-CoV infection in the founder lines results
in dramatically divergent disease outcomes ranging from
mild respiratory and clinical disease symptoms (<5%
weight loss) to fulminant lethal disease in 2 or 3 days
and a wide range in lethal doses ranging from <102 to
>106, depending on the line (data not shown). Another
initial study infected the precursor to the CC (the pre-CC)
with IAV and was limited to a single animal each from
155 lines (69). However, these data from these geneti-
cally unique animals at a single time point were sufficient
to define quantitative trait loci associated with host
responses including virus-induced weight loss, titer, pul-
monary edema, neutrophil recruitment, and transcriptional
expression. Similar results with SARS-CoV (data not
shown) demonstrated the success of this approach even
on such a small-scale experiment. Subsequently, our group
is seeking to identify natural polymorphisms and oligoge-
netic traits that regulate the immune response following
SARS-CoV, IAV, and West Nile Virus (WNV) infection in
the full CC over the next 5 years. Measuring a wide array
of immune parameters at multiple time points in >150
distinct lines, this project will effectively produce the larg-
est and most comprehensive database for in vivo immune
responses, host expression patterns, and disease outcomes
in a reproducible animal model of outbred human popu-
lations following viral infection. Applying systems-based
techniques to these datasets provides the opportunity to
understand the virus–host interaction networks that regu-
late disease severity and protective immunity, leading to
new therapeutic intervention strategies. Together, the
approach has the potential to revolutionize our under-
standing of the immune system and make significant
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contributions to the understanding and treatment of
human disease.
Whole-body plethysmography
For respiratory pathogens such as SARS-CoV and IAV, small
animal models recapitulate many elements of human disease
including viral replication, cell infiltration, and adaptive
immune responses. However, measurement of clinical dis-
ease has been primarily limited to indirect measures like
weight loss and lethality which have little direct correlation
with human disease. Although other measurements, includ-
ing histology and flow cytometry analysis, can provide a
window into respiratory function in vivo, previous studies
suggest that they do not necessarily correlate well with path-
ogenesis and survival (69). Therefore, we sought to add an
additional dimension to systems-based analysis with
measurement of lung function following viral infection.
Using the Buxco whole-body unrestrained plethysmography
system, respiratory function can be tracked in the same ani-
mal over a time course and has already been utilized in
studies for RSV, WNV, and IAV (70–72). In our system,
SARS-CoV, IAV, or mock infected animals are placed into
the plethysmography chamber, and respiratory outputs are
measured every 2 s for a 5 min duration following a set
acclimation period. Measured over a time course, the out-
puts include a variety of direct and derived values that indi-
cate aspects of respiratory function including calculated
airway resistance (penH), breath frequency, lung volumes,
and flow rates. Together, these readouts provide a direct
measure of respiratory function following viral infection and
when combined with resources like the CC, generate high-
throughput datasets ideal for systems-based analysis.
Measuring immune infiltration
While far from a novel procedure, analysis of lung infiltra-
tion by flow cytometry and histopathology has primarily
been used for confirmation and validation purposes rather
than as inputs for systems-based modeling. However, the
combination of pathogens, dose scaling, and varying time
points found in our systems biology infrastructure yields an
enormous amount of high-throughput data ideal for target
generation. Flow cytometry analysis of infected lungs evalu-
ates the composition, kinetics, and magnitude of the
immune infiltrate for a wide array of immune cells.
Similarly, histopathology provides information on the struc-
tural aspects of lung infiltration including airway denuding,
perivascular cuffing, and hyaline membrane formation.
Differences in both flow and histopathology have been pre-
viously shown to influence pathogenesis following viral
infection, yet the genetic factors and host response patterns
that regulate pathogenic or protective responses remain
poorly understood, especially in outbred populations. There-
fore, application of systems-based analysis to these data will
likely yield fruitful targets for further examination by tran-
scriptional or epigenetic profiling of specific cell types
following infection.
Exploring adaptive immunity
While reductionist-based approaches have provided a foun-
dation for our understanding, they have fallen short in
terms of modeling the adaptive immune response for
human diseases. This is because end-stage effector functions
like antibody production and T-cell activation are influenced
by numerous host pathways and complex interactions in a
time-dependent fashion. To understand these pathways
requires probing the adaptive response to virus infection
with systems-based analysis. However, although virus, dose,
and time point are critical elements in initiating the
response, a diverse genetic background is required to gener-
ate sufficient contrast to model and identify key elements of
the adaptive immune response. This diverse system will be
achieved with incorporation of the CC. Building on the
diversity of the CC, viral-specific T-cell responses from
different lines will be identified by intracellular cytokine
staining, surrogate activation marker identification, as well
as peptide tetramer staining of antigen-specific T cells;
acquiring these data will identify key regulators through dif-
ferential expression in the high-throughput datasets. Simi-
larly, antibody neutralization titers and ELISA titers will be
employed to distinguish genes and pathways that contribute
to the end-stage B-cell function. Together, this technique
adds adaptive immune responses as a biological correlate to
refine modeling and identify novel targets related to induc-
tion of adaptive immune responses.
Revolutionizing and rethinking biological modeling
With the development of new outputs and experimental con-
ditions, the task of modeling and integrating multiple vari-
ables gains increased importance. In its infancy, systems
biology relied primarily on RNA expression data as the main
input for its mathematical modeling and target generation. As
the field has matured, new high-throughput data sources were
established as raw data for these modeling approaches. Simi-
larly, the expansion of systems biology also led to the devel-
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opment and application of new modeling paradigms based on
statistical tests (Fischer’s summary statistic), module mapping
(WGCNA), and fold-change z-score (CLR). However, for the
most part, these modeling systems existed in isolation inter-
acting primarily with simple datasets and experimental condi-
tions. Advancement of systems-based modeling requires
integration of these high-throughput datasets, varying experi-
mental systems, and novel mathematical approaches.
Several groups, including ours, have sought to meld these
diverse aspects to develop models that refine and enhance tar-
gets for validation and confirmation within systems biology.
One approach utilizes different high-throughput data types to
generate common, refined targets. For example, our SARS-
DORF6 studies utilized CLR-based modeling of both transcri-
ptomics and proteomic data to identify transcriptional hubs
regulated by karyopherins; this approach narrowed the targets
and provided manageable validation avenues. Another
approach seeks to examine modeling approaches across exper-
imental systems with common biological stimuli. Studies with
IAV H5N1 exemplify this approach as conservation of network
modeling was observed between varying in vitro and in vivo
models for interferon responses, inflammasome, and hypercy-
tokinemia (73). A third approach attempts to bridge varying
mathematical and computational approaches to yield a more
complete picture of complex biological systems. Using this
method, our group combined CLR-based analysis with
WGCNA module mapping to create a blended model system
that helped to identify important regulators influencing patho-
genesis including Tnfrsf1b and Kepi1 (JE McDermott, LE Gra-
linski, AJ Eisfeld, HD Mitchell, A. Bankhead, L Josset, N
Tchitchek, J Chang, G Neumann, SC Tilton, C Li, S Fan, A Schä-
fer, S McWeeney, Y Kawaoka, RS Baric, KM Waters, MG Katz,
in review). Another example generated meta-analysis from
SARS-CoV, IAVs H5N1-VN1203, and H1N1-1918 infection
data at multiple doses using statistical tests, module mapping,
and z-score–based analysis (74). The study suggested that
increased magnitude, rather than differential gene expression,
drove differences in host damage between low and high path-
ogenic infection conditions. Together, these studies illustrate
simple steps taken toward integrating aspects of the modeling
approaches; however, significant advancement is still neces-
sary as systems biology research moves forward.
Among the areas of primary need is the ability to multiplex
high-throughput data in the computation and mathematical
models. With the development and incorporation of numer-
ous new high-throughput data sources including the CC, the
next leap in model design must move beyond single and dual
input analysis. Incorporating multiple biological parameters is
required to understand complex biological systems involved
during infectious disease pathogenesis. Along with develop-
ing new models for areas like whole-body plethysmography,
immune infiltration, and metabolomics, systems biology
teams must devote significant resources toward integrating
these models with other output measures. In addition, incor-
poration of multiple modeling approaches will help refine
and advance the responses; new algorithms like the inferelator
and cross-validation approaches provide a blueprint to these
advances (61, 75). Similarly, modeling approaches including
discriminant analysis via mixed integer programming or prin-
cipal component analysis have been utilized by other systems
biology groups with great success and could be combined
with our approaches to produce more robust models of dis-
ease (14, 15). In addition, efforts to ‘train’ the modeling
approaches are underway, utilizing known biological signa-
tures and datasets to help refine and improve targeting in sim-
ilar, yet unknown conditions. For example, studies with
SARS-CoV mutants lacking NSP16 have defined important
pathways independent of any modeling approach (Menachery
VD, Eisfeld AJ, Josset L, Sims AC, Schaefer A, Proll S, Fan S, Li
C, Neumann G, Tilton SC, Chang J, Gralinski LE, Long C,
Green R, Matzke MM, Webb-Robertson BJ, Shukula AK, Bur-
kett S, Metz TO, Pickles R, Smith RD, Waters KM, Katze MG,
Kawaoka Y, Baric RS, in review); these data were then used to
screen the efficacy of newly developed models to examine
other mutant viruses with similar infection kinetics. A similar
approach was utilized in examination of influenza vaccine
responses (15). Together, these efforts are just a few of the
ways that systems-based modeling can be refined to provide
efficient, effective targeting. While significant commitment is
needed for this possibility to come to fruition, the resulting
models would provide an opportunity to revolutionize our
understanding of complex biological systems.
Validation, translation, and extension
Lack of validation has been a major source of criticism of
systems-based analysis (2), and a concerted effort by the
field is essential for maximizing the long-term sustainability
of the approach. However, the use of reductionist-based
approaches for validation and extension is inherently limited
to our areas of scientific understanding. Often, these studies
utilize knock-out mice, drug treatment, or other reagents
previously generated in the course of reductionist-based
science. While some of these areas are novel for infectious
disease research (Kepi1, Serpine1, etc.), limiting analysis and
validation to these areas is a problem. Therefore, as systems
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biology matures, novel methods and experimental systems
to validate and test targets must be developed beyond the
current scope of reductionist-based approaches. In addition,
these types of experiments should seek to make direct
parallels to human disease and foster development of drug
and therapeutic treatments. Many of the novel techniques
and methods outlined in the data expansion section above
also fit into these parameters. Below we describe several
additional areas of expansion that are applicable to our
respiratory virus infection model.
Examination of allelic variation
Reductionist-based validation approaches often rely on knock-
out and overexpression studies to provide understanding,
using the absence or overabundance of a molecule as a means
to define its function. However, these types of null genetic
mutation are rarely observed in nature, making it difficult to
directly translate these finding into human disease models.
For validation to have a translational impact on human dis-
ease, our studies must use genetic diversity to alter target
gene/pathways functions rather than knock-out or knock-
down studies. The CC allows this type of analysis through
generation of customizable recombinant inbred intercrosses
(76, 77). For example, studies with SARS-CoV have identified
Serpine1, a key component of the urokinase pathway and an
important player in tissue damage/repair following infection.
Serpine1 deficiency results in enhanced disease and pathogene-
sis following SARS-CoV infection, likely due to increased lung
pathology (18). However, the impact of these data remains
unclear with regards to human disease: the vast majority of
people maintain functional Serpine1, but genetic diversity in
this gene or region of the genome may have a significant
impact on pathogenic outcomes and disease severity. To assay
this possibility, we can utilize the CC to generate mouse lines
with allelic diversity in this region of the genome, while
maintaining genetic identity throughout the rest of the gen-
ome (Fig. 5A). Similarly, the genome region could remain sta-
tic and the background shifted to assess the impact of a
specific allele. For Serpine1 in the CC, this means the possibility
of examining the impact of six haplotypes during in vivo infec-
tion (Fig. 5B). Importantly, other analysis can be layered onto
the CC RIX experimental model including predictions based
on SNP consequences (Fig. 5C), structural alterations (78)
(Fig. 5D), and/or epigenetic regulatory factors. In addition,
multiple genes could be analyzed in parallel to assay their alle-
lic impact on each other; while either holding constant or ran-
domizing the majority of the genome, allelic variants can be
shuffled between the two gene regions, creating combinations
to assay their interaction with each other and the global
response (Fig. 5A). For example, systems vaccinology has
identified important genes impacting the antibody response
(TNFRS17 & CaMKIV) and T-cell response (EIF2AK4 & C1QB)
following yellow fever and influenza vaccination (15). Using
the CC, the varying allele combinations could be examined in
the same background and provide a window into the interac-
tions of different gene combinations and pathways.
The allele-based examination using the CC provides a
means to directly measure the impact of specific gene altera-
tions identified in human disease models. This contrast the
traditional knock-out/knock-in approaches and has implica-
tion for targets generated by both reductionist-based
approaches and GWAS. Notably, for systems biology targets,
the CC allows validation of genes and pathways without the
requirement of previously generated reagents alleviating one
of the major issues with validation. Because the CC is based
on natural genetic variation rather than genetic deletions,
this resource also allows for investigations into the role of
genes that cannot be knocked out or knocked down in tradi-
tional validation approaches. This overcomes a major chal-
lenge of systems-based approaches, where many candidate
genes cannot be targeted due to their essential function.
Together, these approaches represent a major leap in the
utilization and validation of systems-based analysis.
Drug targeting
The initial purpose of systems biology was not only
greater understanding of complex biological systems but
also as a platform approach to rapidly identify candidate
drugs and therapies to treat human diseases. While there
have been some successes in this area (79), development
of these reagents for treatment of infectious disease has
been lacking. Moving forward, focus on clinical treatments
provides both validation to systems-based targets as well
as develop useful therapeutics for treating patients. To
achieve this purpose, our group used functional genomics
and computation biology to diagnose virus etiology, fore-
cast disease severity in the lung, and develops a highly
portable screening platform that analytically pinpoints and
then tests the ability of lead compounds to attenuate virus
disease (19). Built upon a database of characterized small
molecules and FDA-approved drugs [e.g. connectivity map
database, Canadian DrugBank, the Pharmacogenomics
Knowledge base, etc.], the approach uses pattern recogni-
tion and multiparametric, multiobjective optimization tech-
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niques to match gene expression changes with drug targets
that possibly reverse those trends and could be repurposed
for use as antiviral therapies.
Using these drug targets, validation studies would analyze
the efficacy of the drugs both in vitro and in vivo for toxicity,
viral replication, and disease pathogenesis. Beginning in com-
mon cell lines with known effective doses (Veros, Hela,
Calu3), we can evaluate the ability of the drug to impact viral
replication using low viral doses to maximize effect. Subse-
quent in vitro studies would use tissue-specific cell lines and
primary cultures to define cell toxicity, viral replication, and
host expression changes as measured by microarray. Drug tar-
gets effective in these areas would be further tested in inbred
models of infection for in vivo efficacy. Finally, a diverse panel
of CC mice would also be tested to ascertain possibility of
drug failure due to genetic diversity. This approach provides a
means to quickly develop drug treatments for human disease
and also validate targets generated by systems biology.
The utility of this approach is illustrated by identification
of drug targets for both SARS-CoV and EMC-CoV. Detailed
transcriptomic analysis of SARS-CoV and EMC2012 host
response networks had demonstrated early upregulated
genes (approximately 200) that are downstream of p38
map kinase signaling pathways. A systematic review of the
FDA database indicated that SB203580, a pyridinyl imidaz-
ole inhibitor of p38 mitogen-activated protein kinase,
Allele varia on
Background varia on











Fig. 5. The collaborative cross offers the opportunity to examine allelic variation in systems-based gene targets. (A) A schematic of three
approaches used to evaluate how allelic diversity in a target gene may alter viral pathogenesis. Allele variation holds the background relatively
constant and shifts the possible gene alleles. Background variation assesses a single allele in multiple backgrounds. Finally, paired combinations
examine the relationship between allele combinations in multiple systems or genome-wide association studies-based targets. (B) Phylogenetic tree
of mouse Serpine1 within the collaborative cross. (C) Consequences of single nucleotide polymorphisms within various CC strains. A. single
nucleotide polymorphisms consequences include untranslated region (Blue); synonymous coding (Green); and non-synonymous coding (Yellow).
(D) Structure of human Serpine1 (78).
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significantly downregulated overlapping sets of genes that
are induced by high path coronaviruses (80). To test com-
pound effectiveness, we infected Vero cells with SARS-CoV
at a MOI of 0.01 and then treated cells with type I IFN or
SB203580. Importantly, SB203580 significantly reduced
both EMC-CoV and SARS-CoV growth (and CPE) in culture,
and in some cases, was equivalent to IFN treatment, sup-
porting our hypothesis that lead compounds for therapeutic
testing and evaluation can be identified by modeling
approaches that compare contrasting expression patterns
during infection and drug treatment. Further testing in tis-
sue-specific cells and in vivo continues for SB203580, but the
data illustrate conceptual support for this approach. A simi-
lar method is planned for other systems biology targets
suggesting that identified drugs may enhance protective
responses mitigated by the Urokinase pathway (e.g. protein
kinase C) or stimulate the TLR3/TLR4/myd88 signaling
pathways (e.g. TLR3- PolyIC, Poly AU, TLR4-Monophospho-
ryl lipid A) (80), protecting against lethal disease.
Predictive, diagnostic biomarkers
Infectious disease susceptibility is governed by numerous
factors including underlying genetics, the age of the
infected, environmental factors, and the dose of the patho-
gen exposure. These factors make treatment more difficult
to prescribe as it is nearly impossible to determine the
appropriate use of aggressive or conservative treatment
options at early time points. Whereas the systems biology
approaches have provided identification of key pathways
that play protective or pathogenic roles after infection, the
next stage of development requires linking these pathway
outcomes with early events to provide prognostic biomar-
kers to aid in treatment of disease (82–85). These studies
will take advantage of the massive functional genomics data-
sets to identify early etiologic and prognostic signature that
track with disease severity across pathogens and in vivo
systems including human (PBMC), mouse, and non-human
primate models. Next, natural genetic variation on biomar-
ker sensitivity and specificity can be evaluated using
resources such as the CC, a reproducible model of human
genetic diversity. Finally, key validated biomarker and prog-
nostic indicators will be integrated into assays for differen-
tial diagnosis and prognosis, linked to computational
algorithms that forecast FDA drugs and other treatments that
may attenuate pathogenesis. In this way, development of
biomarkers via systems-based approaches has the potential
to revolutionize the way human diseases are treated with an
eye toward likely outcome dictating the intervention
strategies.
Conclusion
Systems biology has documented potential for enhancing
our understanding of complex biological systems. Based pri-
marily on genomic high-throughput data, modern modeling
approaches, and reductionist-based validation methods,
systems-based studies have provided novel insights for infec-
tious disease aspects including innate immunology, clinical
disease, viral–host interactions, drug targeting, adaptive
immunity, vaccine efficacy, etc. (11–16, 21, 86).
In many ways, systems biology is still in its infancy, and
new developments in data generation, modeling, and valida-
tion approaches will continue to expand, providing enor-
mous opportunities for furthering our understanding of
complex virus–host interaction paradigms and disease
(Fig. 6). For example, high-throughput data has expanded to
include data areas like respiratory function, phosphoproteo-
mics, next-generation sequencing, and metabolomics that
provide a different type of output to model with the possi-
bility for unique targets. Similarly, the constant evolution,
application, and refinement of modeling approaches provide
improved targets for downstream analyses and increased
understanding. Finally, both reductionist- and systems-based
Fig. 6. Novel experimental conditions, modeling approaches, and
validation methods will continue to expand the power of systems
biology and provide further insights into complex biological
interactions. Depictions of current and future data types are divided
into the three faces on the systems biology cube. The right face
includes experimental approaches that have and will be utilized for
high-throughput data generation. The left face illustrates modeling
approaches and outputs from current and future studies. Finally, the
top face shows results for validation and expansion of systems-based
targets.
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groups provide novel techniques and new areas for valida-
tion and incorporation. Together, these current and future
elements will exponentially extend the power of systems-
based analysis and permit examination of even more
complex questions including the role of genetic variation in
infectious disease processes, the creation of novel therapeu-
tics for respiratory virus infection, and integration of human
GWAS findings into model systems for validation.
As potential becomes reality with regards to data, tech-
niques, and resources, a significant change must also accom-
pany our overall research mindset. The interaction between
disciplines like virology and computational modeling must
be strengthened and expanded to leverage the utility of the
new outputs and models. In addition, a renewed effort is
required to develop hybrid approaches that employ the best
elements of both reductionist- and systems-based methods.
Finally, training a new generation of scientist with these
tenets is paramount in the acceptance and maximum utiliza-
tion of this approach. While reductionist-based approaches
have provided the foundation of our understanding of many
critically important biological phenomena, a new era of big
datasets is emerging which will not only provide a more
holistic view of complex diseases but also reveal new virus–
host paradigms that regulate disease severity and provide for
new opportunities for the treatment and amelioration of
human disease.
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